Jennifer Y Barraclough

List of Publications by Year
in descending order

18	589	840119 11	887659 17
papers	citations	h-index	g-index

19	19	19	1056
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. Journal of the American Heart Association, 2015, 4, e002128.	1.6	206
2	Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clinical Science, 2016, 130, 1237-1246.	1.8	102
3	Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2021, 10, e018993.	1.6	65
4	Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study. Clinical Therapeutics, 2019, 41, 2172-2181.	1.1	33
5	Neutrophil-derived microparticles are released into the coronary circulation following percutaneous coronary intervention in acute coronary syndrome patients. Bioscience Reports, 2017, 37, .	1.1	25
6	MicroRNAs as Prognostic Markers in Acute Coronary Syndrome Patientsâ€"A Systematic Review. Cells, 2019, 8, 1572.	1.8	25
7	Weight Gain Trajectories from Birth to Adolescence and Cardiometabolic Status in Adolescence. Journal of Pediatrics, 2019, 208, 89-95.e4.	0.9	20
8	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1072-1083.	2.2	20
9	Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease. International Journal of Cardiology, 2018, 253, 138-144.	0.8	18
10	A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 444-455.	1.0	17
11	Sex differences in aortic augmentation index in adolescents. Journal of Hypertension, 2017, 35, 2016-2024.	0.3	13
12	Relation of Body Mass Index to Outcomes in Acute Coronary Syndrome. American Journal of Cardiology, 2021, 138, 11-19.	0.7	10
13	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938.	2.2	10
14	Early and late childhood telomere length predict subclinical atherosclerosis at age 14â€¯yrs. â€“ The CardioCAPS study. International Journal of Cardiology, 2019, 278, 250-253.	0.8	9
15	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. Cells, 2021, 10, 2699.	1.8	7
16	Vascular transcriptome landscape ofTrail^{â^'/â^'}mice: Implications and therapeutic strategies for diabetic vascular disease. FASEB Journal, 2020, 34, 9547-9562.	0.2	6
17	Why Are We Forgetting Patients With Peripheral Arterial Disease?. Heart Lung and Circulation, 2021, 30, 939-942.	0.2	1
18	Comprehensive assessment of epicardial and microcirculatory involvement in coronary artery disease. Coronary Artery Disease, 2015, 26, e41-e42.	0.3	0